Please visit our MS learning channel on YouTube, which provides hundreds of MS related topics from many of our video recorded education programs and archived here: -- Be empowered with MS views and news. Opt-in with us:

~~ Scroll left side of this blog for needed resources. Also, use our 'search by topic' tool, to find specific information.

Disclaimer: 'MS Views and News' DOES NOT endorse any products or services found on this blog. It is up to you to seek advice from your healthcare provider. The intent of this blog is to provide information on various medical conditions, medications, treatments, and procedures for your personal knowledge and to keep you informed of current health-related issues. It is not intended to be complete or exhaustive, nor is it a substitute for the advice of your physician. Should you or your family members have any specific medical problem, seek medical care promptly.


Tuesday, August 26, 2014

Biogen’s Tysabri, Novartis’ Gilenya Being Considered For Funding In New Zealand Health System

The Pharmaceutical Management Agency(PHARMAC) is considering a funding proposal that includes five treatments for multiple sclerosis (MS), namely two key MS drugs,  Biogen‘sTysabri and Novartis‘ Gilenya, that are not currently funded. PHARMAC is the New ZealandCrown agency that decides, on behalf of District Health Boards, which medicines and related products are subsidized, which means that natalizumab and fingolimod may start to be prescribed by the New Zealand community and public hospitals.


 Keep CURRENT and up to date, with MS News and Information
Sign-up for emails 



No comments: